Evidence map›Paper›PMID 39598522›Full record

ReviewPharmaceutics2024

Revolutionizing Eye Care: Exploring the Potential of Microneedle Drug Delivery.

Satish Rojekar, Swapnali Parit, Amol D Gholap, Ajit Manchare, Sopan N Nangare, Navnath Hatvate, Vrashabh V Sugandhi, Keshav Raj Paudel, Rahul G Ingle

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Satish RojekarDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-3301-5941
Swapnali ParitInstitute of Chemical Technology, Marathwada Campus, Jalna 431203, India.
Amol D GholapDepartment of Pharmaceutics, St. John Institute of Pharmacy and Research, Palghar 401404, India.ORCID 0000-0003-4145-4060
Ajit ManchareInstitute of Chemical Technology, Marathwada Campus, Jalna 431203, India.
Sopan N NangareDepartment of Pharmaceutics, H. R. Patel Institute of Pharmaceutical Education and Research, Shirpur 425405, India.ORCID 0000-0002-6513-3336
Navnath HatvateInstitute of Chemical Technology, Marathwada Campus, Jalna 431203, India.ORCID 0000-0002-3388-3247
Vrashabh V SugandhiCollege of Pharmacy & Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.ORCID 0000-0001-7072-5910
Keshav Raj PaudelCentre for Inflammation, School of Life Sciences, Faculty of Science, Centenary Institute and University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0002-3591-2080
Rahul G IngleDatta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research (Deemed to Be University)-DMIHER, Wardha 442107, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microneedle technology revolutionizes ocular drug delivery by addressing challenges in treating ocular diseases. This review explores its potential impact, recent advancements, and clinical uses. This minimally invasive technique offers precise control of drug delivery to the eye, with various microneedle types showing the potential to penetrate barriers in the cornea and sclera, ensuring effective drug delivery. Recent advancements have improved safety and efficacy, offering sustained and controlled drug delivery for conditions like age-related macular degeneration and glaucoma. While promising, challenges such as regulatory barriers and long-term biocompatibility persist. Overcoming these through interdisciplinary research is crucial. Ultimately, microneedle drug delivery presents a revolutionary method with the potential to significantly enhance ocular disease treatment, marking a new era in eye care.

Indexed as

biocompatibilityeye careglaucomamicroneedlesocular drug delivery

Identifiers

PMID39598522
PMCPMC11597228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.